VistaGen Therapeutics Q3 Loss Increases but Beats Estimates

VistaGen Therapeutics reports a larger loss for Q3, with earnings at -$0.46 per share. However, it beat street estimates of -$0.52, indicating a mixed outcome for investors.

Date: 14-02-2025

AI Rating: 5

Earnings Per Share (EPS)
VistaGen Therapeutics Inc reported an EPS of -$0.46, an increase from last year's -$0.22. While this represents a growing loss, it is better than the expected -$0.52, suggesting that while the company is not profitable, it performed better than analysts predicted.

Revenue Growth
The company’s revenue fell 43.9%, amounting to $0.23 million compared to $0.41 million last year. This significant decrease in revenue can indicate challenges in business performance and may negatively impact investor confidence.

Net Income
Net income also worsened, with a loss of -$14.09 million, compared to a loss of -$6.35 million the previous year, which portrays a trend of worsening financial health.

Stocks: VTGN